Today the Retraction Watch list of Nobelists who have retracted papers bids Verabschiedung to Max Planck. After days of scrutiny, Springer Nature has restored two papers by Planck, who won the Nobel ...
A crucial study that enabled the vasculitis drug avacopan, branded as Tavneos, to gain regulatory approval has been retracted by the New England Journal of Medicine (NEJM).1 Tavneos has been at the ...
Update: As of July 7, Springer Nature has reinstated the two essays by Max Planck. The articles now denote the initial retraction date (December 23, 2011) and the ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The mistake briefly introduced false information into a morning already ...
The most consequential job openings in American government come with lifetime tenure, and they appear so infrequently that even rumors of a vacancy can take over newspaper front pages and cable news a ...
Editor's note: Earlier today, we erroneously published a story saying that Supreme Court Justice Samuel Alito was retiring. Neither Alito nor the court's public information office has announced his ...
The news outlet quickly removed the article, which was written by NPR’s seasoned Supreme Court reporter, Nina Totenberg, from its website. By Benjamin Mullin See more of our coverage in your search ...
NPR has retracted a story about Supreme Court Justice Samuel Alito after mistakenly reporting on Tuesday that he was retiring. The move comes after the original article by Nina Totenberg sparked panic ...
The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated ...
Introduction The optimal endovascular treatment strategy for medium and distal vessel occlusions remains undefined given the anatomical challenges of distal vessels. Stent retriever-assisted ...
NEJM editors cited post–database lock readjudication after trial unblinding, undisclosed to two academic authors, as inconsistent with proper research conduct and sufficient to retract the publication ...
June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s (AMGN.O), opens new tab rare-disease drug, citing ...